Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00955760|
Recruitment Status : Completed
First Posted : August 10, 2009
Last Update Posted : February 8, 2011
• Assess the effects of poly-specific cytochrome P450 and drug-transporter induction by repeated dose Rifampicin (600 mg/day) co-administration on the single-dose pharmacokinetics of Neramexane.
• To assess safety and tolerability of Neramexane single dose treatment alone and co-administration of a Neramexane single dose with a Rifampicin repeated dose treatment.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Neramexane||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Masking:||None (Open Label)|
|Official Title:||A Single Center, Open-Label, Three Periods, Fixed Sequence Design Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00955760
|AAIPharma Deutschland gmbH & Co. KG|
|Neu-Ulm, Bayern, Germany, 89231|